Medtronic PLChas been one of the most acquisitive companies in recent years, clocking seven deals in 2014. And in spite of splashing a record $43 billion on Medtronic Minimally Invasive Therapies, the biggest pure-play medtech company doesn’t look like it’s planning to stop shopping any time soon. (See[A#01150202003].)
So what areas is Medtronic looking at? Diagnostics and personalized medicine could be sectors of interest, hinted Geoffrey Martha, senior vice president of strategy and development, at the recent IATI...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?